Arrowhead Pharmaceuticals, Inc.
ARWR
Rang in Aktien
#2373
Arrowhead Pharmaceuticals, Inc., founded in 1989 and based in Pasadena,... Arrowhead Pharmaceuticals, Inc., founded in 1989 and based in Pasadena, California, is a biopharmaceutical company dedicated to discovering and advancing innovative treatments for complex and challenging-to-treat diseases within the United States. The company's extensive therapeutic pipeline primarily leverages RNA interference (RNAi) technology. Among its advanced clinical programs are: ARO-AAT, a Phase II therapeutic targeting liver diseases associated with alpha-1 antitrypsin deficiency; ARO-APOC3, which is undergoing both Phase 2b and Phase 3 clinical evaluations for hypertriglyceridemia; ARO-ANG3, currently in Phase 2b development to reduce the production of angiopoietin-like protein 3; and ARO-HIF2, a Phase 1b candidate designed to treat clear cell renal cell carcinoma. Arrowhead also has several compounds in earlier clinical development, including ARO-HSD in Phase 1/2a for other liver diseases, ARO-ENaC in Phase 1/2a, aimed at decreasing the epithelial sodium channel alpha subunit in lung airways, and ARO-C3, also in Phase 1/2a, for complement-mediated diseases. Further expanding its diverse portfolio, the company is actively developing ARO-Lung2 for chronic obstructive pulmonary disorder (COPD), ARO-DUX4 for facioscapulohumeral muscular dystrophy, ARO-XDH for uncontrolled gout, and ARO-COV for COVID-19 and other pulmonary-borne pathogens. Beyond its core internal programs, Arrowhead is involved in the progression of JNJ-3989, a subcutaneously administered RNAi therapeutic for chronic hepatitis B virus infection; Olpasiran, intended to reduce apolipoprotein A production; and ARO-AMG1, which targets genetically validated cardiovascular pathways. Strategic collaborations are integral to Arrowhead's development efforts. The company holds a licensing and research agreement with Janssen Pharmaceuticals, Inc. for the co-development of ARO-JNJ1, ARO-JNJ2, and ARO-JNJ3, all RNAi therapeutics focused on liver-expressed targets. Additionally, Arrowhead has a licensing and research partnership with Takeda Pharmaceuticals U.S.A., Inc. to develop an RNAi therapeutic candidate specifically for liver disease.
Aktienkurs
$59.06
Zuletzt synchronisiert: 2026-10-20
Marktkapitalisierung
$8.34B
Veränderung (1 Tag)
3.20%
Veränderung (1 Jahr)
55.30%
Land
US
Handel Arrowhead Pharmaceuticals, Inc. (ARWR)
Kategorie
Healthcare
Umsatz von Arrowhead Pharmaceuticals, Inc. (ARWR)
Umsatz im Jun 2026 TTM: $669.50M
Laut den aktuellen Finanzberichten von Arrowhead Pharmaceuticals, Inc. beträgt der derzeitige Umsatz des Unternehmens (TTM) $669.50M. Im Jahr 2024 erzielte das Unternehmen einen Umsatz von $3.55M ein Rückgang im Vergleich zu dem Umsatz im Jahr 2023, der $240.74M betrug. Der Umsatz ist der Gesamtbetrag, den ein Unternehmen durch den Verkauf von Waren oder Dienstleistungen erzielt. Im Gegensatz zum Gewinn werden keine Ausgaben abgezogen.
Umsatzverlauf für Arrowhead Pharmaceuticals, Inc. von 2000 bis 2026
Umsatz am Ende jedes Jahres
| Jahr | Umsatz | ändert |
|---|---|---|
| 2026 (TTM) | $669.50M | -19.28% |
| 2025 | $829.45M | 23,258.15% |
| 2024 | $3.55M | -98.52% |
| 2023 | $240.74M | -1.03% |
| 2022 | $243.23M | 75.89% |
| 2021 | $138.29M | 57.16% |
| 2020 | $87.99M | -47.87% |
| 2019 | $168.80M | 945.67% |
| 2018 | $16.14M | -48.60% |
| 2017 | $31.41M | 19,736.49% |
| 2016 | $158.33K | -58.55% |
| 2015 | $382.00K | 118.29% |
| 2014 | $175.00K | -39.71% |
| 2013 | $290.27K | 97.63% |
| 2012 | $146.88K | -50.40% |
| 2011 | $296.14K | -52.24% |
| 2010 | $620.10K | -83.50% |
| 2009 | $3.76M | 188.38% |
| 2008 | $1.30M | 7.88% |
| 2007 | $1.21M | 102.87% |
| 2006 | $595.46K | 0.81% |
| 2005 | $590.68K | 200.90% |
| 2004 | $196.31K | 0.00% |
| 2003 | 0.00 | -100.00% |
| 2002 | $2.27K | -75.67% |
| 2001 | $9.31K | -62.57% |
| 2000 | $24.88K | 0.00% |
Umsatz vergleichbarer Unternehmen oder Wettbewerber
| Unternehmen | Umsatz | Umsatzunterschied | Land |
|---|---|---|---|
| $12.62B | 1,785.65% |
US
|
|
| $2.23B | 232.79% |
US
|
|
| $15.74B | 2,251.67% |
AU
|
|
| - | - |
CH
|
|
| $6.02B | 799.38% |
NL
|
